These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 11337299)

  • 1. Results of a screening program for prostate cancer in patients scheduled for abdominoperineal resection for colorectal pathologic findings.
    Terris MK; Wren SM
    Urology; 2001 May; 57(5):943-5. PubMed ID: 11337299
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Free prostate-specific antigen improves prostate cancer detection in a high-risk population of men with a normal total PSA and digitalrectal examination.
    Uzzo RG; Pinover WH; Horwitz EM; Parlanti A; Mazzoni S; Raysor S; Mirchandani I; Greenberg RE; Pollack A; Hanks GE; Watkins-Bruner D
    Urology; 2003 Apr; 61(4):754-9. PubMed ID: 12670560
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Transrectal ultrasound-guided biopsy of prostate voxels identified as suspicious of malignancy on three-dimensional (1)H MR spectroscopic imaging in patients with abnormal digital rectal examination or raised prostate specific antigen level of 4-10 ng/ml.
    Kumar V; Jagannathan NR; Kumar R; Thulkar S; Gupta SD; Hemal AK; Gupta NP
    NMR Biomed; 2007 Feb; 20(1):11-20. PubMed ID: 16894640
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prostate cancer screening before and after abdominoperineal resection: recommendations, biopsy, and therapeutic techniques.
    Pérez LM; Mekras JA; Neshat AA; Weems WS; Shook EL
    Surgery; 1994 Jun; 115(6):745-50. PubMed ID: 7515197
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biopsy-proved prostate cancer in 100 consecutive men with benign digital rectal examination and elevated serum prostate-specific antigen level. Prevalence and pathologic characteristics.
    Guthman DA; Wilson TM; Blute ML; Bergstralh EJ; Zincke H; Oesterling JE
    Urology; 1993 Aug; 42(2):150-4. PubMed ID: 7690170
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Clinical utility of available diagnostic tests in prostatic carcinoma. Results of 500 biopsies. II. Rectal palpation, PSA, and transrectal echography].
    Rodríguez Rodríguez R; Mayayo Dehesa T; Galbis Sanjuan F; Jiménez Cidre M; Burgos Revilla FJ; Gómez dos Santos V; García González R
    Arch Esp Urol; 1997 May; 50(4):339-45. PubMed ID: 9313042
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Normal range prostate-specific antigen versus age-specific prostate-specific antigen in screening prostate adenocarcinoma.
    el-Galley RE; Petros JA; Sanders WH; Keane TE; Galloway NT; Cooner WH; Graham SD
    Urology; 1995 Aug; 46(2):200-4. PubMed ID: 7542822
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prostate cancer screening within a prostate specific antigen range of 3 to 3.9 ng./ml.: a comparison of digital rectal examination and free prostate specific antigen as supplemental screening tests.
    Mäkinen T; Tammela TL; Hakama M; Stenman UH; Rannikko S; Aro J; Juusela H; Määttänen L; Auvinen A
    J Urol; 2001 Oct; 166(4):1339-42. PubMed ID: 11547069
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [The role of the absolute value and "density" of the prostate-specific antigen estimated echographically in the selection of patients to undergo a biopsy in suspected prostatic carcinoma. A comparison between PSA, palpation and echography in 95 patients undergoing echo-guided endorectal prostatic biopsy].
    Di Donna A; Bazzocchi M; Guerra UP; Bendini M; De Biasi F; Caminiti F; Delendi M
    Radiol Med; 1993; 85(1-2):84-9. PubMed ID: 7683136
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Determination of the percentage of free prostate-specific antigen helps to avoid unnecessary biopsies in men with normal rectal examinations and total prostate-specific antigen of 4-10 ng/ml.
    Martínez-Piñeiro L; Tabernero A; Contreras T; Madero R; Lozano D; López-Tello J; Alonso-Dorrego JM; Picazo ML; González Gancedo P; Martínez-Piñeiro JA; de La Peña JJ
    Eur Urol; 2000 Mar; 37(3):289-96. PubMed ID: 10720854
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of prostate needle biopsies in a population-based screening study: the impact of borderline lesions.
    Hoedemaeker RF; Kranse R; Rietbergen JB; Kruger AE; Schröder FH; van der Kwast TH
    Cancer; 1999 Jan; 85(1):145-52. PubMed ID: 9921986
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Early diagnosis of prostatic carcinoma by random biopsies in 60 patients clinically negative but with PSA greater than 8.9 ng/ml].
    Bianchi A; Bottanelli A; Baroni G; Rovellini P; Sciaraffia G; Toia G; Marcelli G
    Arch Ital Urol Androl; 1997 Dec; 69(5):313-8. PubMed ID: 9477617
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Transperineal prostate biopsy after abdominoperineal resection.
    Shinohara K; Gulati M; Koppie T; Terris MK
    J Urol; 2003 Jan; 169(1):141-4. PubMed ID: 12478122
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of Digital Rectal Examination and Serum Prostate Specific Antigen in the Early Detection of Prostate Cancer: Results of a Multicenter Clinical Trial of 6,630 Men.
    Catalona WJ; Richie JP; Ahmann FR; Hudson MA; Scardino PT; Flanigan RC; DeKernion JB; Ratliff TL; Kavoussi LR; Dalkin BL; Waters WB; MacFarlane MT; Southwick PC
    J Urol; 2017 Feb; 197(2S):S200-S207. PubMed ID: 28012755
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diagnostic significance of digital rectal examination and transrectal ultrasonography in men with prostate-specific antigen levels of 4 NG/ML or less.
    Yamamoto T; Ito K; Ohi M; Kubota Y; Suzuki K; Fukabori Y; Kurokawa K; Yamanaka H
    Urology; 2001 Dec; 58(6):994-8. PubMed ID: 11744475
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of sextant transrectal prostate biopsy plus additional far lateral cores in improving cancer detection rates in men with large prostate glands.
    Kobayashi T; Nishizawa K; Watanabe J; Ogura K; Mitsumori K; Ide Y
    Int J Urol; 2004 Jun; 11(6):392-6. PubMed ID: 15157208
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prostate cancer screening with prostate specific antigen in spinal cord injured men.
    Pramudji CK; Mutchnik SE; DeConcini D; Boone TB
    J Urol; 2002 Mar; 167(3):1303-5. PubMed ID: 11832718
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Detection rates of nonpalpable prostate cancer in Korean men with prostate-specific antigen levels between 2.5 and 4.0 ng/mL.
    Kim HS; Jeon SS; Choi JD; Kim W; Han DH; Jeong BC; Seo SI; Lee KS; Lee SW; Lee HM; Choi HY
    Urology; 2010 Oct; 76(4):919-22. PubMed ID: 20303152
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biopsy indication--a predictor of pathologic stage among men with preoperative serum PSA levels of 4.0 ng/mL or less and T1c disease.
    Freedland SJ; Mangold LA; Epstein JI; Partin AW
    Urology; 2004 May; 63(5):887-91. PubMed ID: 15134972
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: results of a multicenter clinical trial of 6,630 men.
    Catalona WJ; Richie JP; Ahmann FR; Hudson MA; Scardino PT; Flanigan RC; DeKernion JB; Ratliff TL; Kavoussi LR; Dalkin BL; Waters WB; MacFarlane MT; Southwick PC
    J Urol; 1994 May; 151(5):1283-90. PubMed ID: 7512659
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.